Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Brendon L NeuenMegumi OshimaRajiv AgarwalClare ArnottDavid Z I CherneyRobert EdwardsAnna Maria LangkildeKenneth W MahaffeyDarren K McGuireBruce C NealVlado PerkovicAnnpey PongMarc S SabatineItamar RazTadashi ToyamaChristoph WannerDavid C WheelerStephen D WiviottBernard ZinmanHiddo J Lambers HeerspinkPublished in: Circulation (2022)
SGLT2 inhibitors reduce the risk of serious hyperkalemia in people with type 2 diabetes at high cardiovascular risk or with chronic kidney disease without increasing the risk of hypokalemia.